Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

被引：22
|
作者：
Wethington, Stephanie L.
Shah, Payal D.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Morgan, Mark Aloysuis
Torigian, Drew A.
Pagan, Cheyenne
Rodriguez, Diego
Domchek, Susan M.
Drapkin, Ronny
Shih, Le-Ming
Smith, Simon
Dean, Emma
Armstrong, Deborah Kay
Gaillard, Stephanie
Simpkins, Fiona
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Hosp Univ Penn, Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA
[6] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] AstraZeneca, Cambridge, England
[9] Univ Manchester, Manchester, Lancs, England
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[12] Johns Hopkins Sch Med, Baltimore, MD USA
[13] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5516
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer.
    Wolford, Juliet Elizabeth
    Bai, Jiaru
    Eskander, Ramez Hassef
    Keller, Robin
    Minion, Lindsey
    Chan, John K.
    Monk, Bradley J.
    Tewari, Krishnansu Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
    Westin, Shannon Neville
    Litton, Jennifer Keating
    Williams, Rochelle A.
    Shepherd, Christopher J.
    Brugger, Wolfram
    Pease, Elizabeth J.
    Soliman, Pamela T.
    Frumovitz, Michael M.
    Levenback, Charles F.
    Sood, Anil
    Meyer, Larissa
    Moulder, Stacy L.
    Valero, Vicente
    Saleem, Sadia
    Rodriguez, Anna Marie
    Cyriac, Annies
    Engerman, Laverne
    Samuel, Christine
    Mills, Gordon B.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
    Xuan, Jiachen
    Pearson, Richard B.
    Sanij, Elaine
    MOLECULAR & CELLULAR ONCOLOGY, 2020, 7 (06)
  • [24] Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
    Ivy, S. Percy
    Liu, Joyce F.
    Lee, Jung-Min
    Matulonis, Ursula A.
    Kohn, Elise C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 597 - 611
  • [25] Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).
    Reichert, Zachery R.
    Devitt, Michael Edward
    Alumkal, Joshi J.
    Smith, David C.
    Caram, Megan Veresh
    Palmbos, Philip
    Vaishampayan, Ulka N.
    Alva, Ajjai Shivaram
    Braun, Thomas
    Yentz, Sarah Elizabeth
    Tsao, Phoebe A.
    Dreicer, Robert
    Cackowski, Frank Cameron
    Shah, Neel
    Dean, Emma
    Smith, Simon
    Heath, Elisabeth I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
    Lampert, Erika J.
    Zimmer, Alexandra
    Padget, Michelle
    Cimino-Mathews, Ashley
    Nair, Jayakumar R.
    Liu, Yingmiao
    Swisher, Elizabeth M.
    Hodge, James W.
    Nixon, Andrew B.
    Nichols, Erin
    Bagheri, Mohammad H.
    Levy, Elliott
    Radke, Marc R.
    Lipkowitz, Stanley
    Annunziata, Christina M.
    Taube, Janis M.
    Steinberg, Seth M.
    Lee, Jung-Min
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4268 - 4279
  • [27] Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors.
    Shapiro, Geoffrey I.
    Basu, Bristi
    El-Khoueiry, Anthony
    Postel-Vinay, Sophie
    Im, Seock-Ah
    Rha, Sun Young
    Friedman, Claire F.
    Italiano, Antoine
    Kim, Yong Man
    Lim, Myong Cheol
    Roux, Rene
    Liu, Joyce F.
    Sanai, Elhan
    Smith, Simon A.
    Smith, Claire
    El Farhi, Sarah
    Lau, Alan
    Lukashchuk, Natalia
    Dean, Emma
    Krebs, Matthew G.
    CANCER RESEARCH, 2022, 82 (12)
  • [28] BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCAmutant ovarian cancer
    Gupta, Nitasha
    Huang, Tzu-Ting
    Nair, Jayakumar. R. R.
    An, Daniel
    Zurcher, Grant
    Lampert, Erika. J. J.
    McCoy, Ann
    Cimino-Mathews, Ashley
    Swisher, Elizabeth. M. M.
    Radke, Marc. R. R.
    Lockwood, Christina. M. M.
    Reichel, Jonathan. B. B.
    Chiang, Chih-Yuan
    Wilson, Kelli. M. M.
    Cheng, Ken Chih-Chien
    Nousome, Darryl
    Lee, Jung-Min
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (701)
  • [29] The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells
    Jette, N.
    Radhamani, S.
    Arthur, G.
    Ye, R.
    Goutam, S.
    Boylos, A.
    Petersen, L.
    Bose, P.
    Bebb, G.
    Lees-Miller, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S570 - S571
  • [30] Targeting ATR and AKT pathways promotes cell death in PARP inhibitor-resistant ovarian cancer cells by increasing DNA damage and lethal replication stress
    Huang, Tzu-Ting
    Chiang, Chih-Yuan
    Gupta, Nitasha
    Wilson, Kelli
    Cheng, Ken Chih-Chien
    Lee, Jung-Min
    CANCER RESEARCH, 2022, 82 (12)
12345